Long-term inclisiran data suggest The Medicines Company/Alnylam drug will flourish in pivotal study, disrupt 'bad' cholesterol market
Ahead of the keenly anticipated pivotal late-stage readout for its Alnylam $ALNY-partnered long-acting cholesterol fighter inclisiran, The Medicines Company on Saturday afternoon unveiled long-term Phase II data that suggested the biannual-dosed drug is as safe and effective as the approved once-monthly Repatha and Praluent.
Unlike Repatha from Amgen $AMGN, as well as Praluent from Regeneron $REGN and Sanofi $SNY — which work by inhibiting the PCSK9 protein and thereby diminishing LDL-C or “bad” cholesterol — inclisiran is a siRNA therapy designed to curb the production of the PCSK9 protein at its source in the liver to oust LDL-C from the bloodstream.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.